Exasol

Hybrid Analytics Will Serve Finance And Healthcare Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

23.1%

3.2%

23.1%

3.2%

You can edit this narrative until May 12 6:02 AM. Then, changes will post as Updates.

Author's Valuation

€5.148.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

€5.1

48.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.03%

Software revenue growth rate

1.16%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.24%

Calculation

€6.33m

Earnings '28

25.13x

PE Ratio '28

€158.99m

Market Cap '28

€158.99m

Market Cap '28

26.58m

No. shares '28

€5.98

Share Price '28

€5.98 Share Price '28

Discounted to 2025 @ 6.24% p.a.

€4.99

Fair Value '25